Limited Benefit of Adjuvant Chemotherapy in Pathological Stage II–III Non-small Cell Lung Cancer Lacking Lymphatic, Vascular, and Pleural Invasion

Abstract Purpose Adjuvant chemotherapy (AC) improves survival in patients with resected stage II–III non-small cell lung cancer (NSCLC); however, its benefits may not be universal. We aimed to identify subgroups in which the benefit of AC may be limited. Methods In this multicenter study, we retrospectively analyzed 1,307 patients with pathological stage II–III NSCLC who underwent complete resection (R0) between 2010 and 2022. Patients were stratified according to the presence of lymphatic (Ly), vascular (V), or pleural (pl) invasion. Overall survival (OS) and cumulative incidence of recurrence (CIR) were compared between the AC and non-AC groups using multivariate Cox regression and Fine–Gray competing-risk models. Results Overall, 775 patients did not receive AC, and 532 did. In the subgroup without Ly, V, or pl invasion (low-risk group), AC did not significantly improve OS (5-year OS: 79.3% vs. 74.3%, P = 0.66) or CIR (5-year CIR: 28.9% vs. 27.6%, P = 0.79). In patients with Ly, V, or pl invasion (high-risk group), AC was associated with better OS (5-year OS: 81.2% vs. 51.2%, P < 0.01) and lower CIR (5-year CIR: 49.9% vs. 52.1%, P = 0.04). Among patients with pathological node-positive disease (pN+), an OS benefit was observed only in the high-risk group. Conclusions In completely resected stage II–III NSCLC, the absence of Ly, V, and pl invasion identified a low-risk subgroup in which the survival benefit of AC appeared limited, particularly in pN0 disease. Pathological invasion status may help identify patients for whom the benefit of AC warrants further evaluation.

Authors

Publication Details

Journal
Annals of Surgical Oncology
Published
2026-11-14
DOI
https://doi.org/10.1245/s10434-026-20802-1
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Limited Benefit of Adjuvant Chemotherapy in Pathological Stage II–III Non-small Cell Lung Cancer Lacking Lymphatic, Vascular, and Pleural Invasion

Yuya Hirai, Takahiro Mimae, Norifumi Tsubokawa, Hiroyuki Ito et al.
Annals of Surgical Oncology
Lung Cancer Diagnosis and Treatment
article

Limited Benefit of Adjuvant Chemotherapy in Pathological Stage II–III Non-small Cell Lung Cancer Lacking Lymphatic, Vascular, and Pleural Invasion

Yuya Hirai, Takahiro Mimae, Norifumi Tsubokawa, Hiroyuki Ito, Yujin Kudo, Yoshihiro Miyata, Norihiko Ikeda, Takuya Nagashima, Morihito Okada
article en

Abstract

Abstract Purpose Adjuvant chemotherapy (AC) improves survival in patients with resected stage II–III non-small cell lung cancer (NSCLC); however, its benefits may not be universal. We aimed to identify subgroups in which the benefit of AC may be limited. Methods In this multicenter study, we retrospectively analyzed 1,307 patients with pathological stage II–III NSCLC who underwent complete resection (R0) between 2010 and 2022. Patients were stratified according to the presence of lymphatic (Ly), vascular (V), or pleural (pl) invasion. Overall survival (OS) and cumulative incidence of recurrence (CIR) were compared between the AC and non-AC groups using multivariate Cox regression and Fine–Gray competing-risk models. Results Overall, 775 patients did not receive AC, and 532 did. In the subgroup without Ly, V, or pl invasion (low-risk group), AC did not significantly improve OS (5-year OS: 79.3% vs. 74.3%, P = 0.66) or CIR (5-year CIR: 28.9% vs. 27.6%, P = 0.79). In patients with Ly, V, or pl invasion (high-risk group), AC was associated with better OS (5-year OS: 81.2% vs. 51.2%, P < 0.01) and lower CIR (5-year CIR: 49.9% vs. 52.1%, P = 0.04). Among patients with pathological node-positive disease (pN+), an OS benefit was observed only in the high-risk group. Conclusions In completely resected stage II–III NSCLC, the absence of Ly, V, and pl invasion identified a low-risk subgroup in which the survival benefit of AC appeared limited, particularly in pN0 disease. Pathological invasion status may help identify patients for whom the benefit of AC warrants further evaluation.

Annals of Surgical Oncology
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon